The Group highlighted the commitment of the Hôpital Charles-Le Moyne to breast cancer treatment research on May 13, 2025 by unveiling a recognition plaque that will adorn a wall of Centre intégré de cancérologie de la Montérégie.
The CISSS de la Montérégie-Centre-Hôpital Charles-Le Moyne is currently one of 13 Quebec sites that is part of our research consortium.
“We are proud of the Hôpital Charles-Le Moyne’s participation in this research consortium, which provides people with breast cancer with access to innovative alternatives to traditional treatments. As a group, we can do better together to care for people with this disease,” said Richard Deschamps, President and CEO of the CISSS de la Montérégie-Centre.
Co-founders Susan McPeak and Charles Sirois took the opportunity to emphasize that our Group, by joining forces with its member hospitals, brings real benefits to people with breast cancer in Quebec. “Our model is a win-win for patients, member institutions, and their researchers. To date, more than 1,000 patients have been included in nearly sixty clinical trials conducted within the Group, which has positioned itself as the gateway to breast cancer clinical trials in Quebec,” said Ms. McPeak and Mr. Sirois.
From left to right :
Nathalie Boudreau, Executive Director of Fondation Hôpital Charles-LeMoyne
Mathieu Lebeau, Clinical Research Coordinator at CISSSMC
Charles Sirois, Co-Founder McPeak-Sirois Group
Julien Terrier, Deputy Director in Cancerology at CISSSMC
Dr. Samuel Martel, Medical Oncologist at CISSSMC
Cloé Rodrigue, Research Director at CISSSMC
Susan McPeak, Co-Founder McPeak-Sirois Group
Audrey Couture, Assistant to the Research Director at CISSSMC
Nathalie Moreau, Director of the Cancer Program at CISSSMC
